KIT is a frequent target for epigenetic silencing in cutaneous melanoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The receptor tyrosine kinase KIT and its ligand, stem cell factor (SCF), are crucial for melanocyte survival and proliferation.
• Activating KIT mutations are oncogenic drivers and therapeutic targets in specific melanoma subtypes.

Purpose of the Study:

• To investigate the role of KIT promoter hypermethylation in cutaneous melanoma pathogenesis.
• To determine the correlation between KIT hypermethylation, KIT expression, and melanoma drivers.
• To explore the influence of stem cell factor (SCF) on KIT expression and methylation.

Main Methods:

• Whole-genome screening for aberrant promoter methylation in melanoma cell lines and tissues.
• In vitro and in vivo assessment of KIT promoter activity and KIT expression.
• Treatment with the demethylating agent 5-aza-2'-deoxycytidine.
• Correlation analysis with known melanoma drivers and SCF exposure.

Main Results:

• KIT promoter hypermethylation was identified in a significant proportion of melanoma cell lines and clinical samples.
• Hypermethylation inversely correlated with KIT promoter activity and KIT expression.
• KIT expression was restored upon demethylating agent treatment.
• SCF exposure led to reduced KIT expression and increased KIT promoter methylation.
• KIT hypermethylation showed no correlation with other major melanoma drivers.

Conclusions:

• Frequent KIT promoter hypermethylation represents a mechanism for KIT inactivation in cutaneous melanoma.
• Distinct KIT signaling pathways may play opposing roles in different melanoma subtypes.
• SCF may exert selection pressure favoring KIT loss through hypermethylation.